Phenotypic Precision Medicine in Advanced Prostate Cancer
Phenotypic Precision Medicine in Advanced Prostate Cancer
Phenotypic Precision Medicine in Advanced Prostate Cancer
Robert DillardPhenotypic Precision Medicine in Advanced Prostate Cancer | November 18, 2022
A polygenic hazard score (PHS290) is able to stratify US veterans of diverse ancestry for lifetime risk of prostate cancer.
Read More
A study assessed the link between benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
A corrected genetic risk score (GRS) based on non-European racial/ethnic populations is more appropriate for genetic testing.
Genetic testing rates are low for prostate cancer.
Daniel Tennenbaum, MDPhenotypic Precision Medicine in Advanced Prostate Cancer | November 15, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on new research in phenotypic precision medicine.
Daniel Tennenbaum, MDPhenotypic Precision Medicine in Advanced Prostate Cancer | October 27, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of pain in prostate cancer.
Prostate cancer risk stratifying can identify men at the highest risk of dying before the age of 75.
A family history of prostate cancer (PCa) is strongly associated with a risk of colon cancer.
A study identified three key genes linked to prognosis of prostate cancer.
A study identified cellular targets for the treatment of prostate diseases.
Daniel Tennenbaum, MDPhenotypic Precision Medicine in Advanced Prostate Cancer | October 3, 2022
Andrew Armstrong, MD ScM FACP, is interviewed by Daniel Tennenbaum, MD on the role of precision medicine in prostate cancer.
Researchers of a study sought to assess the usefulness of the LDN-PSA in detecting prostate cancer.
A recent study assessed DNA 5-hydroxymethylcytosine (5hmC) changes during genitourinary carcinogenesis in prostate cancer.
Electronic health record (EHR) disease classifiers are viable for precision screening classifiers in prostate cancer.
A study uncovered an androgen receptor (AR) network that may identify hotspots for therapy intervention in prostate cancer.
GU Oncology Now EditorsPhenotypic Precision Medicine in Advanced Prostate Cancer | September 8, 2022
Evan Ya-Wen Yu, MD, talks about different types of precision medicine, the future of precision medicine, and more.
A new prostate cancer taxonomy distinguishes patients by genetic ancestry and predicts which cancers may be life-threatening.
Men with a benign histology after TURP have a low risk of aggressive prostate cancer and do not require extensive monitoring.
Combining metformin with testosterone replacement therapy was shown to reduce the effects of prostate and colorectal cancers.
Data from the STOMP and ORIOLE trials showed that many OMPC patients will experience durable response to therapy.
Advertisement
Advertisement